Almac has Successful MHRA Inspection at its Clinical Services UK Site
once again pleased to announce the successful completion of an inspection of
its Clinical Services UK facility located in Craigavon by the Medicines and
Healthcare products Regulatory Agency (MHRA).
The routine inspection, which took place over four days, from
13th – September 16th
the site continues to be compliant with EU Good Manufacturing Practices, with
no critical or major failures observed.
Commenting on the inspection,
“We are extremely pleased with the outcome of our inspection. These
successful results are a positive reflection of all the investment Almac has
made over the past few years in our facilities and recruitment of the best
employees, ensuring that we are a market leader and continue to deliver a
high quality service. Quality is at the core of our ethos – we have three
MHRA approved facilities globally, including our additional FDA assessed US
standards of quality compliance will continue with our new
American Headquarters in
Notes to Editors
The Almac Group comprises five closely integrated divisions offering a
broad range of services from R&D, biomarker discovery and development, API
manufacture, formulation development, clinical trial supply and IXRS
technology (IVRS/IWRS), to commercial-scale manufacture. Almac provides
services to more than 600 companies, including all the world leaders in the
pharmaceutical and biotech sectors.
The company employs over 2,800 individuals and is headquartered in
employees will relocate during the fall.
For more information on Almac, please visit http://www.almacgroup.com Contact: Aileen Murphy email@example.com Tel: +44(0)28-3836-2436
SOURCE Almac Group